发明名称 Compounds inhibiting leucine-rich repeat kinase enzyme activity
摘要 The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
申请公布号 US9493440(B2) 申请公布日期 2016.11.15
申请号 US201414772295 申请日期 2014.02.27
申请人 Merck Sharp & Dohme Corp. 发明人 Miller Michael;Basu Kallol;DeMong Duane;Scott Jack;Li Wei;Stamford Andrew;Poirer Marc;Tempest Paul
分类号 C07D403/04;C07D401/14;C07D405/14;C07D413/14;C07D403/14;C07D409/14;C07D417/14;C07D471/04;C07D471/10;C07D487/04;C07D487/08;C07D487/10;C07D491/107;C07D498/04;C07D498/08;C07D498/10 主分类号 C07D403/04
代理机构 代理人 MacMillan Keith D.;Todaro John C.
主权项 1. A compound of the formula: wherein X1, X2 and X3 are each independently selected from the group consisting of a bond or CReRf; Y is O, CRaRb or NRc; Z is O, CRaRb or NRc; R1 is selected from the group consisting of hydrogen and C1-6 alkyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, hydroxyl, NRcRd, OR5 and (C═O)OR5; R2 is selected from the group consisting of hydrogen and C1-6 alkyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of: a) halo,b) cyano,c) R5,d) R7,e) OR5, andf) NRcRd; R3 is selected from the group consisting of: a) hydrogen, b) C1-6 alkyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, OR5 and NRcRd, c) C3-8 cycloalkyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, OR5 and NRcRd, d) heterocyclyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, oxo, R5, OR5 and NRcRd, e) heteroaryl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, oxo, R5, OR5 and NRcRd; f) C4-8cycloalkenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, OR5 and NRcRd, g) (C═O)R7, h) (C═O)R5, i) S(O)mR5, and j) S(O)mR7; or R2 and R3 can be taken together with the atoms to which they are attached to form a 3 to 8 membered heterocyclic ring, wherein said ring may contain from one to three heteroatoms selected from N, O and S, wherein the sulfur is optionally oxidized to the sulfone or sulfoxide, and which ring is optionally substituted with one to four substituents each independently selected from the group consisting of: a) halo,b) oxo,c) cyano,d) OR5,e) NRcRd,f) SO3H,g) S(O)mR5,h) S(O)mR7 i) R5,j) R6,k) R7,l) (C═O)R5,m) (C═O)OR5,n) (C═O)R7, ando) (C═O)NRcRd; R4 is selected from the group consisting of hydrogen, halo, cyano, OR5, aryl, heteroaryl, C3-8 cycloalkyl, C4-8 cycloalkenyl, C4-8 heterocyclyl and C1-6 alkyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, cyano, OC1-3alkyl, NRcRd and hydroxyl; R5 is selected from the group consisting of hydrogen and C1-6 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of: a) halo,b) hydroxyl,c) OC1-6alkyl,d) NRcRd,e) (C═O)NRcRd,f) S(O)m,g) S(O)mR8,h) S(O)mR7,i) R7, andj) OR7; R6 is C1-6alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl; or R5 and R6 can be taken together with the atoms to which they are attached to form a 4 to 8 membered heterocyclic, 3 to 8 membered carbocyclic, aryl or heteroaryl ring, wherein said heterocyclic and heteroaryl rings may contain from one to three heteroatoms selected from N, O and S, wherein said heterocyclic, carbocyclic, aryl and heteroaryl rings are optionally substituted with one to three substituents independently selected from the group consisting of: a) halo, b) oxo, c) cyano, d) hydroxyl, e) C1-3 alkyl, which is optionally substituted with one to three halo, f) C3-8 cycloalkyl, g) OC1-3alkyl, which is optionally substituted with one to three halo, and h) OC3-8cycloalkyl; R7 is selected from the group consisting of C4-8 heterocyclyl, C3-8 cycloalkyl, C4-8 cycloalkenyl, aryl or heteroaryl, wherein said heterocyclyl, cycloalkyl, cycloalkenyl, aryl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of: a) halo, b) cyano, c) hydroxyl, d) oxo, e) C1-3alkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3alkyl and NRcRd, f) OC1-3alkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3alkyl NRcRd and aryl, g) C3-8 cycloalkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3alkyl and NRcRd, h) aryl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3 alkyl, S(O)mNRcRd, C(O)NRcRd and NRcRd, i) heteroaryl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3alkyl, S(O)mNRcRd, C(O)NRcRd and NRcRd, j) heterocyclyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, OC1-3alkyl and NRcRd, k) C4-8 cycloalkenyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo, cyano, heterocyclyl, OC1-3 alkyl and NRcRd; R8 is hydrogen or C1-6alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of: a) halo, b) cyano, c) hydroxyl, d) OC1-3alkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of hydroxyl, halo and NRcRd, and e) C3-8 cycloalkyl; Ra is selected from the group consisting of hydrogen and C1-6 alkyl; Rb is selected from the group consisting of hydrogen and C1-6 alkyl; Rc is selected from the group consisting of: a) hydrogen andb) C1-3 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, cyano, heteroaryl, aryl, NH(C1-3alkyl), N(C1-3alkyl)2, OC1-6alkyl, and C3-8 cycloalkyl; Rd is selected from the group consisting of: a) hydrogen,b) C3-8 cycloalkyl,c) C3-6 heterocyclyl,d) C1-3 alkyl,e) (C═O)C1-3alkyl,f) aryl, andg) heteroaryl;wherein said cycloalkyl, heterocyclyl, alkyl, aryl and heteroaryl groups are each optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, cyano, R8, SO2R8, OC1-6alkyl and C3-8 cycloalkyl, or Re and Rd can be taken together with the atoms to which they are attached to form a 3 to 8 membered heterocyclic ring, wherein said ring may contain from one to three heteroatoms selected from N, O and S, wherein the sulfur is optionally oxidized to the sulfone or sulfoxide, and which ring is optionally substituted with one to four substituents each independently selected from the group consisting of halo, cyano, hydroxyl, C1-3 alkyl and OC1-3alkyl; Re is selected from the group consisting of hydrogen and C1-3alkyl; Rf is selected from the group consisting of hydrogen and C1-3 alkyl; m is an integer from zero to two,or a pharmaceutically acceptable salt thereof.
地址 Rahway NJ US